Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 2
Development Phase
1
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
0 competitors in Drug Susceptible Pulmonary Tuberculosis
View Full LandscapeTarget Indication
Drug Susceptible Pulmonary Tuberculosis
Clinical Trial
NCT07525427Last updated: 8/17/2026
No patent data available. Pre-approval drugs may not have Orange Book listings.
Dovprela (previously Pretomanid FGK)
Dovprela is indicated in combination with bedaquiline and linezolid, in adults, for the treatment of pulmonary extensively drug resistant (XDR), or treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB). Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Rheumatoid Arthritis
Moderate Chronic Plaque Psoriasis
Carcinoma, Ovarian Epithelial
Arthritis, Rheumatoid
Fabry Disease